The Argentinean Ministry of Health has approved the use of the Sputnik Light vaccine as a single-shot vaccination and a booster injection to combat the SARS-CoV-2 coronavirus, according to the Russian Direct Investment Fund (RDIF).

The Sputnik Light vaccine is based on human adenovirus serotype 26, which is also the initial component of the Sputnik V vaccine, the world's first Covid-19 vaccine, and its administration Argentina approved in December 2020.

Sputnik V was approved by Argentina's National Administration of Drugs, Foods, and Medical Devices based on Russian clinical trial results, with no further investigations required.

Sputnik Light, taken as a single dosage, has a 70% efficiency against infections from the Delta strain of the coronavirus within the first three months following immunization, according to the Gamaleya Scientific Research Institute of Epidemiology and Microbiology.

The Sputnik Light vaccination is 75 percent efficient among participants under the age of 60, according to studies done by that Russian scientific institute based on data from 28,000 citizens in Moscow.

The immunizer is close to the efficacy of the Sputnik V vaccine, which is more than 83 percent effective against the virus and more than 94 percent effective against hospitalization when used as a booster dose for other Delta variant vaccinations, according to the RDIF.